Vercirnon Clinical Trials

Size	Price	Qty
5mg	USD 339
25mg	USD 970

Clinical Trials

Several clinical trials sponsored by ChemoCentryx and GlaxoSmithKline have evaluated Vercirnon for chronic inflammatory gastrointestinal disorders, spanning Phase 2 and Phase 3 studies in celiac disease, Crohn's disease, and ulcerative colitis. Although a ChemoCentryx-sponsored Phase 2 trial in celiac disease was completed, subsequent investigations by GlaxoSmithKline encountered setbacks. Consequently, a Phase 3 study in moderately-to-severely active Crohn's disease was terminated, and a Phase 2 study in ulcerative colitis was withdrawn.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01658605	Withdrawn	Colitis Ulcerative	GlaxoSmithKline	2013-02	Phase 2
NCT01536418	Terminated	Crohn''s Disease	GlaxoSmithKline	2011-11-11	Phase 3
NCT00540657	Completed	Celiac Disease	ChemoCentryx	2007-10	Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Vercirnon product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Vercirnon acts as a potent and selective antagonist of C-C chemokine receptor type 9 (CCR9), binding the receptor to block CCL25-mediated downstream biochemical signaling and inhibit cellular chemotaxis. By suppressing the migration and accumulation of gut-homing immune cells in mucosal tissues, Vercirnon attenuates pathological intestinal inflammation relevant to clinical conditions such as Crohn's disease, ulcerative colitis, and celiac disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).